To require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill requires study on the substitution of interchangeable biological products. It relies on reporting requirements, compliance mandates, and product standards. The main policy areas are Education, Finance, Energy, and Healthcare.
Who Benefits and How
The main beneficiaries are the people, organizations, or agencies identified in the bill's substantive provisions.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Patients and health care consumers affected by the bill would take on compliance duties, and Energy producers and energy supply-chain firms affected by the bill would take on compliance duties.
Key Provisions
- Requires study on the substitution of interchangeable biological products.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill requires study on the substitution of interchangeable biological products.
Key Policy Areas
Education, Finance, Energy, Healthcare
Primary Purpose
The bill requires study on the substitution of interchangeable biological products.
Policy Domains
Whole bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Patients and health care consumers affected by the bill
- Energy producers and energy supply-chain firms affected by the bill
- Educational institutions and students affected by the bill
- Businesses and employers affected by the bill
Legislative Progress
IntroducedMr. Marshall introduced the following bill; which was read twice …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology